← Back to all trials
Not Yet Recruiting
NCT07667868
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 18
Sponsor: BrightPath Biotherapeutics Co., Ltd.
Summary
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of Multiple Myeloma with relapsed or refractory disease.
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
* Adequate organ function.
* Have measurable disease
Exclusion Criteria:
* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.
* Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.
Source: ClinicalTrials.gov (NCT07667868). StuddyBuddy aggregates publicly available trial information.
